Developer docs
API playgroundTry for free, no card

Search company profiles

EHT Technologies

Full company profile

uuid000pobt

Namestring
EHT Technologies
Legal namestring
DiNABIOS
Company typeenum
Private
Founded yearint
2015
Descriptiontext

EHT Technologies, doing business as DiNABIOS, is a Hamburg, Germany-based clinical research organization and life science tools developer founded in 2015 that builds 3D human cardiac tissue technology for preclinical drug development. The company's core scientific platform is Engineered Heart Tissue (EHT), three-dimensional fibrin-based cardiac constructs derived from human induced pluripotent stem cells (hiPSCs), which simulate human heart tissue for cardiac safety and efficacy testing, disease modeling, and precision medicine applications including gene therapy. The technology stack is supported by 30 years of underlying research and is paired with two AI-enabled product layers: DiNAQUBE™, an AI-driven video-optical measurement platform that performs sterile measurements in 90 seconds and analyzes up to 24 EHTs in parallel using automated tissue recognition, and DiNALYTIQS™, a web-based analytics solution with AI-powered classification, automated quality control, and customizable reporting.

EHT Technologies monetizes through two parallel channels. Under its 'from our lab' model, the company provides contract research services including screening and phenotyping packages for early-stage drug discovery, safety and efficacy testing, and molecular biology insights. Under its 'in your lab' model, the DiNAQUBE™ measurement platform is sold or leased to pharmaceutical and biotech customers for in-house operation, supplemented by EHT Tools consumables and equipment. Its target customers are pharmaceutical and biotechnology companies engaged in preclinical cardiac safety and efficacy testing, and Bayer is the only publicly named enterprise customer. Go-to-market is direct enterprise field sales with a global geographic scope, and the company is led by CEO Alexandra Rhoden, PhD. No revenue, funding, or pricing data are publicly disclosed, and the firm operates with 1-10 employees.

Short descriptiontext

EHT Technologies (DiNABIOS) is a Hamburg, Germany-based clinical research organization that develops 3D Engineered Heart Tissues from hiPSCs and AI-driven measurement (DiNAQUBE™) and analytics (DiNALYTIQS™) platforms, serving pharmaceutical and biotech customers in preclinical cardiac safety and efficacy testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHamburg, Germany
HQ citystring
Hamburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
preclinical cardiac testing, engineered heart tissue, stem cell cardiac models, drug safety screening, cardiac phenotyping services
Industry1 code
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
Preclinical Cardiac Safety Testing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Laboratory Services
TypeProfessional Services
Description

Screening and phenotyping services provided from the company's lab for early-stage drug development including drug discovery, safety and efficacy testing, and molecular biology insights.

dinabios.com
2DiNAQUBE™ Technology Platform
TypeHardware Sales
Description

Sale or lease of the DiNAQUBE™ measurement platform for customers to operate in their own laboratories for drug discovery, safety, and efficacy testing.

dinabios.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1DiNAQUBE™
Description

AI-driven measurement platform for video-optical measurements of Engineered Heart Tissues, capable of analyzing up to 24 EHTs in 90 seconds

dinabios.com
+3 more records
Core offering1 text field

EHT Technologies (DiNABIOS) is a clinical research organization that develops and sells life science tools based on Engineered Heart Tissue (EHT) technology, including 3D fibrin-based cardiac constructs from human induced pluripotent stem cells, the AI-driven measurement platform DiNAQUBE™, and the web-based analytics solution DiNALYTIQS™. The company also offers contract-based Screening & Phenotyping services that support cardiac safety and efficacy assessment in early-stage drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Sterile tests completed in 90 seconds
+1 more record
Product overview1 text field

DiNABIOS is a clinical research organization offering a unified platform of 3D human tissue technology products and services. The core offering consists of Engineered Heart Tissues (EHTs) — three-dimensional cardiac constructs derived from human induced pluripotent stem cells — which serve as the foundation for all downstream applications. The DiNAQUBE™ is an AI-driven measurement platform that performs video-optical analysis of EHT contractions, while DiNALYTIQS™ is the complementary web-based data analytics solution for interpreting the resulting measurements. The company also provides Screening & Phenotyping services for early-stage drug development and offers specialized EHT Tools for laboratory use.

Product and service1 record
1DiNAQUBE™ Measurement Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Japan-based stem cell company providing hiPSC-derived products and drug discovery services, including cardiac applications. Directly comparable to DiNABIOS as both serve pharma customers with hiPSC-based drug discovery and safety testing tools.

TypeDirect peer
Description

Belgium-based biotechnology company specializing in hiPSC-derived cardiac cells and 3D tissues for drug discovery and cardiac safety testing. Directly comparable to DiNABIOS as both serve pharmaceutical customers with hiPSC-based cardiac models and preclinical safety/efficacy services.

TypeDirect peer
Description

UK-based CRO specializing in cardiac safety ion channel screening and integrated cardiac safety assay services. Directly comparable to DiNABIOS as both provide cardiac safety testing services to pharma with a focus on early-stage drug development.

TypeBroad incumbent
Description

Large global preclinical CRO offering comprehensive cardiac safety testing and broader drug development services. Comparable to DiNABIOS as a broad incumbent offering overlapping cardiac safety testing as part of a much wider services portfolio.

TypeDirect peer
Description

Germany-based company developing automated cardiac safety screening instruments and platforms (e.g., CardioExcyte 96). Directly comparable to DiNABIOS as both sell measurement platforms to pharma for non-invasive, long-term cardiac safety and efficacy assessment.

TypeDirect peer
Description

UK-based provider of hiPSC-derived cells, including cardiomyocytes, and custom assay services for drug discovery. Directly comparable to DiNABIOS as both offer hiPSC-based cell products and screening/phenotyping services to pharmaceutical customers.

TypeDirect peer
Description

Leading provider of hiPSC-derived cardiomyocytes (iCell) and other cell types for drug discovery, disease modeling, and safety pharmacology. Directly comparable to DiNABIOS as both supply pharma with hiPSC-derived cardiac products and supporting assays for preclinical cardiac safety testing.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EHT Technologies

Preclinical Cardiac Safety Testingeht-technologies.com

EHT Technologies (DiNABIOS) is a Hamburg, Germany-based clinical research organization that develops 3D Engineered Heart Tissues from hiPSCs and AI-driven measurement (DiNAQUBE™) and analytics (DiNALYTIQS™) platforms, serving pharmaceutical and biotech customers in preclinical cardiac safety and efficacy testing.

What EHT Technologies does

EHT Technologies, doing business as DiNABIOS, is a Hamburg, Germany-based clinical research organization and life science tools developer founded in 2015 that builds 3D human cardiac tissue technology for preclinical drug development. The company's core scientific platform is Engineered Heart Tissue (EHT), three-dimensional fibrin-based cardiac constructs derived from human induced pluripotent stem cells (hiPSCs), which simulate human heart tissue for cardiac safety and efficacy testing, disease modeling, and precision medicine applications including gene therapy. The technology stack is supported by 30 years of underlying research and is paired with two AI-enabled product layers: DiNAQUBE™, an AI-driven video-optical measurement platform that performs sterile measurements in 90 seconds and analyzes up to 24 EHTs in parallel using automated tissue recognition, and DiNALYTIQS™, a web-based analytics solution with AI-powered classification, automated quality control, and customizable reporting.

EHT Technologies monetizes through two parallel channels. Under its 'from our lab' model, the company provides contract research services including screening and phenotyping packages for early-stage drug discovery, safety and efficacy testing, and molecular biology insights. Under its 'in your lab' model, the DiNAQUBE™ measurement platform is sold or leased to pharmaceutical and biotech customers for in-house operation, supplemented by EHT Tools consumables and equipment. Its target customers are pharmaceutical and biotechnology companies engaged in preclinical cardiac safety and efficacy testing, and Bayer is the only publicly named enterprise customer. Go-to-market is direct enterprise field sales with a global geographic scope, and the company is led by CEO Alexandra Rhoden, PhD. No revenue, funding, or pricing data are publicly disclosed, and the firm operates with 1-10 employees.

EHT Technologies firmographics

Firmographics
Name
EHT Technologies
Legal name
DiNABIOS
Website
https://eht-technologies.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
EHT Technologies (DiNABIOS) is a Hamburg, Germany-based clinical research organization that develops 3D Engineered Heart Tissues from hiPSCs and AI-driven measurement (DiNAQUBE™) and analytics (DiNALYTIQS™) platforms, serving pharmaceutical and biotech customers in preclinical cardiac safety and efficacy testing.
Ownership category
akta.pro rank

EHT Technologies industry classification

Industry
Product category
Preclinical Cardiac Safety Testing
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Preclinical cardiac testing
  • Engineered heart tissue
  • Stem cell cardiac models
  • Drug safety screening
  • Cardiac phenotyping services

Where EHT Technologies is headquartered

Location

Headquarters

HQ city
Hamburg
HQ country
Germany
HQ region
Europe

Markets served

EHT Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Laboratory Services: Screening and phenotyping services provided from the company's lab for early-stage drug development including drug discovery, safety and efficacy testing, and molecular biology insights.
  2. DiNAQUBE™ Technology Platform: Sale or lease of the DiNAQUBE™ measurement platform for customers to operate in their own laboratories for drug discovery, safety, and efficacy testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

EHT Technologies product offering

Product offering

Core offering

EHT Technologies (DiNABIOS) is a clinical research organization that develops and sells life science tools based on Engineered Heart Tissue (EHT) technology, including 3D fibrin-based cardiac constructs from human induced pluripotent stem cells, the AI-driven measurement platform DiNAQUBE™, and the web-based analytics solution DiNALYTIQS™. The company also offers contract-based Screening & Phenotyping services that support cardiac safety and efficacy assessment in early-stage drug development.

Product overview

DiNABIOS is a clinical research organization offering a unified platform of 3D human tissue technology products and services. The core offering consists of Engineered Heart Tissues (EHTs) — three-dimensional cardiac constructs derived from human induced pluripotent stem cells — which serve as the foundation for all downstream applications. The DiNAQUBE™ is an AI-driven measurement platform that performs video-optical analysis of EHT contractions, while DiNALYTIQS™ is the complementary web-based data analytics solution for interpreting the resulting measurements. The company also provides Screening & Phenotyping services for early-stage drug development and offers specialized EHT Tools for laboratory use.

Differentiator

Problem solved

Functional benefit

Brands

  • DiNAQUBE™: AI-driven measurement platform for video-optical measurements of Engineered Heart Tissues, capable of analyzing up to 24 EHTs in 90 seconds
  • DiNALYTIQS™
  • EHT Tools
  • DiNAQUBE™

Products and services

  • DiNAQUBE™ Measurement Platform

Quantifiable outcome

  • Sterile tests completed in 90 seconds
  • +1 more outcomes

Companies that use EHT Technologies

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

EHT Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

EHT Technologies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

EHT Technologies competitors and assessment

Company assessment

Direct peers

  • Reprocell: Japan-based stem cell company providing hiPSC-derived products and drug discovery services, including cardiac applications. Directly comparable to DiNABIOS as both serve pharma customers with hiPSC-based drug discovery and safety testing tools.
  • Ncardia: Belgium-based biotechnology company specializing in hiPSC-derived cardiac cells and 3D tissues for drug discovery and cardiac safety testing. Directly comparable to DiNABIOS as both serve pharmaceutical customers with hiPSC-based cardiac models and preclinical safety/efficacy services.
  • Metrion Biosciences: UK-based CRO specializing in cardiac safety ion channel screening and integrated cardiac safety assay services. Directly comparable to DiNABIOS as both provide cardiac safety testing services to pharma with a focus on early-stage drug development.
  • Nanion Technologies: Germany-based company developing automated cardiac safety screening instruments and platforms (e.g., CardioExcyte 96). Directly comparable to DiNABIOS as both sell measurement platforms to pharma for non-invasive, long-term cardiac safety and efficacy assessment.
  • Axol Bioscience: UK-based provider of hiPSC-derived cells, including cardiomyocytes, and custom assay services for drug discovery. Directly comparable to DiNABIOS as both offer hiPSC-based cell products and screening/phenotyping services to pharmaceutical customers.
  • FUJIFILM Cellular Dynamics: Leading provider of hiPSC-derived cardiomyocytes (iCell) and other cell types for drug discovery, disease modeling, and safety pharmacology. Directly comparable to DiNABIOS as both supply pharma with hiPSC-derived cardiac products and supporting assays for preclinical cardiac safety testing.

Broad incumbents

  • Charles River Laboratories: Large global preclinical CRO offering comprehensive cardiac safety testing and broader drug development services. Comparable to DiNABIOS as a broad incumbent offering overlapping cardiac safety testing as part of a much wider services portfolio.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

EHT Technologies social profiles

Digital presence

EHT Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EHT Technologies leadership team

Management profile

Number of profiles

Profiles1 record

EHT Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EHT Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EHT Technologies

What does EHT Technologies do?

EHT Technologies (DiNABIOS) is a clinical research organization that develops and sells life science tools based on Engineered Heart Tissue (EHT) technology, including 3D fibrin-based cardiac constructs from human induced pluripotent stem cells, the AI-driven measurement platform DiNAQUBE™, and the web-based analytics solution DiNALYTIQS™. The company also offers contract-based Screening & Phenotyping services that support cardiac safety and efficacy assessment in early-stage drug development.

Is EHT Technologies a public or private company?

EHT Technologies is a private company. It is classified as unknown and is currently operating.

When was EHT Technologies founded?

EHT Technologies was founded in 2015. It employs 1 to 10 people.

Where is EHT Technologies based?

EHT Technologies is headquartered in Hamburg, Germany, in the Europe region.

How does EHT Technologies make money?

Two revenue lines are on record. Laboratory Services are the primary driver. The others are diNAQUBE™ Technology Platform.

Who are EHT Technologies's main competitors?

Direct peers on record are Reprocell, Ncardia, Metrion Biosciences, Nanion Technologies, Axol Bioscience and FUJIFILM Cellular Dynamics. Charles River Laboratories is listed as a broad incumbent.

Does EHT Technologies have an API?

No public API is recorded for EHT Technologies.

What industry is EHT Technologies in?

EHT Technologies's product category is Preclinical Cardiac Safety Testing. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals